Edward Tenthoff
Stock Analyst at Piper Sandler
(0.69)
# 2244
Out of 5,329 analysts
227
Total ratings
35.29%
Success rate
-9.42%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
IPSC Century Therapeutics | Maintains: Overweight | 4 2 | 0.55 | 263.64% | 8 | Mar 20, 2025 | |
DYN Dyne Therapeutics | Maintains: Overweight | 53 48 | 12.24 | 292.16% | 6 | Feb 28, 2025 | |
MESO Mesoblast | Reiterates: Overweight | 15 24 | 12.19 | 96.88% | 5 | Feb 7, 2025 | |
LEGN Legend Biotech | Reiterates: Overweight | 78 78 | 34.63 | 125.24% | 4 | Dec 30, 2024 | |
XNCR Xencor | Upgrades: Overweight | 20 30 | 11.05 | 171.49% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 62 45 | 14.43 | 211.85% | 10 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 296 296 | 260.1 | 13.8% | 7 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 115 69 | 27.34 | 152.38% | 12 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 9 4 | n/a | n/a | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 6 1 | 0.71 | 40.85% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 104 65 | 6.91 | 840.67% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 18 | 1.95 | 823.08% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 35 | 12.87 | 171.95% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 11 11 | 1.05 | 947.62% | 6 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 20 20 | n/a | n/a | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 3 3 | 1.35 | 122.22% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 13 5 | 0.03 | 16566.67% | 6 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 8 3 | 0.76 | 294.74% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 16 16 | 5.01 | 219.36% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 105 105 | 38.79 | 170.69% | 6 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 4 6 | 1.28 | 368.75% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 150 150 | n/a | n/a | 4 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 120 80 | n/a | n/a | 5 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 6 5 | 1.35 | 270.37% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 13 15 | 4.51 | 232.59% | 3 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 39 56 | 35.16 | 59.27% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 8 10 | n/a | n/a | 3 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 5 2 | n/a | n/a | 2 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 13 | n/a | n/a | 2 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 70 55 | 7.16 | 668.16% | 6 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 6 7 | n/a | n/a | 2 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 28 31 | 0.99 | 3031.31% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 6 1 | n/a | n/a | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 13 20 | n/a | n/a | 5 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 4 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 6 5 | n/a | n/a | 3 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 90 | 3.8 | 2268.42% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 6 2 | n/a | n/a | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 13 6 | 0.49 | 1124.49% | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 140 180 | 9.52 | 1790.76% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 37 44 | 17.66 | 149.15% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 160 60 | n/a | n/a | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 76 37 | 9.46 | 291.12% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 175 100 | n/a | n/a | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 112332 32560 | 0.5 | 6511900% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 250 354 | 654.28 | -45.89% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 105 135 | 1.14 | 11742.11% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 261 323 | 506.61 | -36.24% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 80 25 | n/a | n/a | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 33 36 | 39.43 | -8.7% | 2 | Feb 16, 2021 |